Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma
2011-005912-27Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Onartuzumab + bevacizumab with Placebo + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-005912-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005912-27.